Invasive breast carcinomas in Ghana: High frequency of high grade, basal-like histology and high EZH2 expression

Breast Cancer Research and Treatment

Volumn 135, Issue 1, 2012, Pages 59-66

  Pang, Judy ^a   Toy, Kathy A ^a   Griffith, Ken A ^a,b   Awuah, Baffour ^c   Quayson, Solomon ^c   Newman, Lisa A ^a,b   Kleer, Celina G ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c Komfo Anoyke Teaching Hospital (KATH)   (Ghana)

Author keywords

African American; Basal like; Breast cancer; Enhancer of zeste 2; EZH2; Health disparity; Triple negative

Indexed keywords

TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ARTICLE; BASAL LIKE BREAST CANCER; BENIGN TUMOR; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; GHANA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GHANA; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASMS, BASAL CELL; POLYCOMB REPRESSIVE COMPLEX 2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84865122721     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2055-z     Document Type: Article

References (44)

1. Smigal C et al (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56(3):168-183 (Pubitemid 43847927)
2. Eley JW et al (1994) Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA 272(12):947-954 (Pubitemid 24288549)
3. Smith-Bindman R et al (2006) Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann Intern Med 144(8):541-553 (Pubitemid 46768143)
4. Diaz LK et al (2007) Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 14(6):419-430 (Pubitemid 350307665)
5. Carey LA et al (2006) Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 295(21):2492-2502 (Pubitemid 43854964)
6. Kim MJ et al (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37(9):1217-1226 (Pubitemid 44286991)
7. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26(15):2568-2581
8. Yang XR et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16(3):439-443 (Pubitemid 46548646)
9. Livasy CA et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19(2):264-271 (Pubitemid 43117611)
10. Fulford LG et al (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49(1):22-34 (Pubitemid 43972917)
11. Ding L et al (2006) Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res 66(8):4095-4099
12. Kleer CG et al (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100(20):11606-11611 (Pubitemid 37205983)
13. Alford SH et al (2012) Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Breast Cancer Res Treat 132(2):429-437
14. Pietersen AM et al (2008) EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 10(6):R109
15. Bachmann IM et al (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24(2):268-273 (Pubitemid 46622055)
16. Raaphorst FM et al (2003) Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5(6):481-488 (Pubitemid 38045085)
17. Gonzalez ME et al (2009) Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 28(6):843-853
18. Chase A, Cross NC (2011) Aberrations of EZH2 in cancer. Clin Cancer Res 17(9):2613-2618
19. Stark A, Kleer CG, Martin I, Baffour A, Nsiah-Asare A, Takyi V, Braman M, Zarbo R, Wicha MS, Newman LA (2010) African ancestry and higher prevalence of triple negative breast cancer: findings from an international study. Cancer 116(21):4926-4932
20. Huo D et al (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 27(27):4515-4521
21. Gonzalez ME, DuPrie ML, Krueger H, Merajver SD, Ventura AC, Toy KA, Kleer CG (2011) Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res 71(6):2360-2370
22. Kunju LP et al (2011) EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol 24(6):786-793
23. Newman LA et al (2006) Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24(9):1342-1349 (Pubitemid 46621996)
24. Chlebowski RT et al (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97(6):439-448 (Pubitemid 40528607)
25. Nalwoga H et al (2007) Frequency of the basal-like phenotype in African breast cancer. APMIS 115(12):1391-1399
26. Ijaduola TG, Smith EB (1998) Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. J Natl Med Assoc 90(9):547-551 (Pubitemid 128504046)
27. Awadelkarim KD et al (2011) Basal-like phenotype in a breast carcinoma case series from Sudan: prevalence and clinical/pathological correlations. Patholog Res Int 2011:806831
28. Rosen PP (2008) Rosen's breast pathology, in Rosen's breast pathology. In: Rosen PP (ed) Lippincott Williams & Wilkins, Philadelphia
29. Collett K et al (2006) Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12(4):1168-1174 (Pubitemid 43342505)
30. Bracken AP et al (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22(20):5323-5335 (Pubitemid 37279943)
31. Gong Y et al (2011) Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117(24):5476-5484
32. Ding L, Kleer CG (2006) Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res 66(19):9352-9355 (Pubitemid 44623628)
33. Chen H, Rossier C, Antonarakis SE (1996) Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2. Genomics 38(1):30-37 (Pubitemid 26423910)
34. Laible G et al (1997) Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J 16(11):3219-3232 (Pubitemid 27234960)
35. Sewalt RG et al (1998) Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol 18(6):3586-3595 (Pubitemid 28240531)
36. Laible G et al (1999) The murine polycomb-group genes Ezh1 and Ezh2 map close to Hox gene clusters on mouse chromosomes 11 and 6. Mamm Genome 10(3):311-314 (Pubitemid 29390523)
37. Varambally S et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907):624-629
38. Kuzmichev A et al (2004) Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell 14(2):183-193 (Pubitemid 38515646)
39. Su IH et al (2005) Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121(3):425-436 (Pubitemid 40692302)
40. van der Vlag J, Otte AP (1999) Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 23(4):474-478
41. Huang L, Pardee AB (2000) Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6(10):849-866
42. Miranda TB et al (2009) DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8(6):1579-1588
43. Tan J et al (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21(9):1050-1063 (Pubitemid 46686474)
44. Puppe J et al (2009) BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res 11(4):R63